UPC Update - HOFFMANN EITLE · The PPA (Protocol to the Agreement on a Unified Patent Court on...
Transcript of UPC Update - HOFFMANN EITLE · The PPA (Protocol to the Agreement on a Unified Patent Court on...
1 Life Science IP Seminar 2017
Dr. Thorsten Bausch
UPC Update
European Patent Attorney, Patentanwalt | Partner
2 Life Science IP Seminar 2017
Entry into Force – Ratification Update
Future of UPC post Brexit
UPC Revocation vs. EPO Opposition
3
Ratification: Status Quo
Yellow: out - not an EU member state
Red: out - does not want to sign
or ratify
Orange: no current information
Dark green: expected to ratify soon
Light green: has ratified
UK: special (will exit EU, but most
probably stil l ratify UPCA before
Brexit...)
Life Science IP Seminar 2017
4
DIMMI QUANDO, SAG MIR WANN?
ENTRY INTO FORCE – WHEN?
2014 2015 2016 2017 2018 2019???
Life Science IP Seminar 2017
5
Three Instruments must be ratified
The UPCA
DE (and UK) still missing
The PPA (Protocol to the Agreement on a Unified Patent Court on
provisional application)
2 more member states still missing
AT, BG, MT and PT have ratified UPCA, but not yet consented to PPA
Supporters hope for GR, EE, LT or SI to ratify and consent soon
Target date of 29 May was missed
The Protocol on Privileges and Immunity
Not yet through UK Parliaments
RATIFICATION UPCA – MORE COMPLEX THAN YOU MIGHT THINK
Life Science IP Seminar 2017
6
UK ratification process is ongoing, despite political will of
“take back control of our laws” and PM statement ”And we
are not leaving only to return to the jurisdiction of the
European court of justice.”
RATIFICATION UK
Life Science IP Seminar 2017
7
RATIFICATION UK
The UK needs to sign the Protocol on Privileges and Immunities. [Done]
The signed Protocol will need to be laid before Parliament for 21 days
(Commenced on January 20; [Done])
A Statutory Instrument (SI) on Privileges and Immunities will need to be finalised
and laid before the Westminster and Scottish Parliaments (has happened in
Westminster, but not as yet in Holyrood)
The SI will be subject to an affirmative procedure which means that there will be
committee debates in both Houses of Westminster and also in the Holyrood
Parliament;
For the SI that passes through Westminster there will be both Commons and Lords
committees. The procedure will be broadly similar as for the SI related to the UPC
earlier in the year but will also include Privy Council approval;
Following approval of the SIs in the Westminster and Scottish parliaments, the rest
is formalities, the UPC Agreement will be ratified via an internal procedure between
the UKIPO and the Foreign Office.
Protocol on Privileges and Immunities
Life Science IP Seminar 2017
8
So, where are we now in the UK?
UK has a new parliament and a new government
Brexit talks with EU have (finally!) started, but seem to be difficult
Uncertain whether general Brexit talk climate will impact UK and/or
DE ratification
Very unlikely that ratification process will be completed before the
summer break
Unclear whether a sufficient number of further states will consent
to PPA before summer break
Entry in force will not be before 1Q 2018!
ENTRY INTO FORCE
Life Science IP Seminar 2017
9
Where are we now in Germany?
DE ratification successfully passed parliament, but deposit of
instrument of ratification is delayed/stayed for two reasons
IT system not yet ready – new CMS version about to be published in 1-2
weeks
German Federal Constitutional Court has asked the President to wait with
signing the ratification law until it has decided on a new constitutional complaint
(2 BvR 739/17)
UPC Preparatory Committee has meanwhile given up on its
previously estimated launch date of 1 December 2017.
As of now, no new date has been officially announced
RATIFICATION DE
Life Science IP Seminar 2017
10
Assuming that
The UK deposits its instruments of ratification after the summer
break of Parliament
PPA is consented by at least 13 states
The IT is ready to go
Germany deposits its instruments of ratification after the UK but
still before the election in September
The UPC might start operation on 1 March 2018
Two sunrise periods might begin on 1 December 2017
For declaring an opt out before the UPC
For filing a request for unitary effect at the EPO
And 13 months later (1 April 2019) the UK will leave the EU…
LAUNCH OF EP-UE AND UPC – MOST OPTIMISTIC SCENARIO
Then
Life Science IP Seminar 2017
11
A few things can still go wrong…
The new UK government may reconsider its position on the UPCA
and request that the UK’s future in the UPCA be clarified prior to
ratification
Germany and the other UPC member states may switch to plan B
w/o the UK
The German Federal Constitutional Court may require that a Court
be established that is competent to overturn final EPO decisions
and that the EPC in its present form violates Germany’s Basic Law
due to insufficient separation of powers
LAUNCH OF EP-UE AND UPC – PESSIMISTIC SCENARIO
Life Science IP Seminar 2017
13
Question #1: What happens after Brexit?
PART II – AFTER LAUNCH...
Only this lady might know…
UK will ratify “without compromising our
position in the Brexit negotiations”
At a minimum, if the UK wants to stay
in, a new international agreement will
have to be concluded
UK will have to acknowledge
supremacy of EU law and CJEU for
purposes of patent disputes
UK should ensure that GB part of EP-
UE will be converted to EP(GB) patent
EU (and CJEU?) will have to agree that
a non-EU state may (from now on)
participate in the UPCA, contrary to the
prevailing understanding of C1/09
Life Science IP Seminar 2017
14
General Politics
EUROPE AT ITS BEST
UK government wants to “take back control of our
laws” and ”And we are not leaving only to return
to the jurisdiction of the European court of
justice.” (Guardian)
Merkel tells Britain no 'cherry-picking' in Brexit
talks (Reuters)
Chancellor Angela Merkel told Britain on Tuesday it
will not be able to cherry-pick the parts of the
European Union it wants, such as the single
market, without accepting principles like free
movement when it negotiates its exit from the bloc.
Life Science IP Seminar 2017
16
But when it comes to patents…
EUROPE AT ITS BEST
UK government considers UPCA as an “international agreement”,
rather than something related to the EU, and does not think that
CJEU and UPC jurisdiction on patent matters stands in the way of
the UK’s “control of our laws”
Rest of Europe seems to have no problem with UK cherry-picking
part of the EU law, i.e. patent law.
Life Science IP Seminar 2017
17
EPO Opposition vs. UPC Revocation
When to use which proceeding?
PART III
Life Science IP Seminar 2017
18
Basic Similarities
Post-grant Opportunity to attack a European Patent
and have it revoked
Contentious Proceedings
o Between Opponent(s)/Plaintiff(s) on one side and the Patentee/Defendant on the other side
o Opponent/Plaintiff has substantial procedural rights just like the patentee
o Neutral deciding body: EPO OD/TBA or UPC
o Technical expertise on the bench
The result is a decision about the validity and shape of
the patent:
o Revocation of the patent
o Limitation of the patent / Maintenance in Amended Form
o Dismissal of the attack / Maintenance in Full
Life Science IP Seminar 2017
19
Lack of Patentability – Lack of Novelty
• Art. 54(2)
• Art. 54(3)
– Lack of Inventive Step
– Lack of Industrial
Applicability
– Violation of Morality
Insufficient disclosure
Added Matter
Grounds of Attack: Art. 100 EPC, Art. 138 EPC, Art. 139(2) EPC, Art. 65 UPCA
Lack of Patentability – Lack of Novelty
• Art. 54(2)
• Art. 54(3)
• Earlier unpublished national
applications
– Lack of Inventive Step
– Lack of Industrial Applicability
– Violation of Morality
Insufficient disclosure
Added Matter
Extension of scope after grant
Lack of Entitlement
Life Science IP Seminar 2017
21
When to use EPO Opposition Proceedings
If you are still within the 9 month opposition period
If your budget is limited
If you can afford waiting for a decision
If the patent has been opted out
If you are interested in invalidating the patent in non UPC
countries (e.g. ES, PL...)
If the patent mainly suffers from added matter problems or
even an inescapable trap problem
If your prior art clearly anticipates the patented invention
If you want to use a straw man
Life Science IP Seminar 2017
23
When to use UPC Revocation Action
If you have missed the opposition period
If your (initial) budget is sufficient
If you have a good case and may hope for success and
remuneration of your costs
If you need a quick decision
If the patent is invalid for extension of scope of protection after
grant, lack of entitlement or lack of novelty over earlier filed but
unpublished national application
If the patent does not only suffer from added matter problems
If cannot clearly show obviousness using the EPO‘s problem -
solution-approach, but have other good obviousness arguments
(e.g. bonus effect falling into skilled person’s leap when doing
the obvious).
Life Science IP Seminar 2017
26
When to use both?
If you MUST win
If costs play no big role
If you have found new and pertinent prior art that you can
no longer introduce into the pending proceedings
If you want to apply pressure on the patentee and force
him to come up with his arguments and claim amendments
as soon as possible
To recover part of your costs if you have already almost
won EPO opposition proceedings (?)
Life Science IP Seminar 2017
27
Recital 1 of AC Decision on scale of recoverable cost ceilings
Life Science IP Seminar 2017
Article 69 of the Agreement qualifies the general rule that the unsuccessful party shall
bear the successful party’s costs by a number of principles, which serve as important
safeguards when the Court makes its decision on costs, by allowing for exceptions from
the general rule or limiting its application. (...)
Firstly, only reasonable and proportionate legal costs and other expenses incurred by
the successful party may be recovered from the unsuccessful party.
Moreover, equity may also serve as a self-standing ground for rendering the general
rule inapplicable.
Furthermore, (...) in exceptional circumstances the Court may order the parties to bear
their own costs, or apply a different apportionment of cost, based on equity.
Unnecessary costs caused to the Court or the other party shall be borne by the party
incurring them, which means that even the successful party has to reimburse costs
caused that are deemed unnecessary by the Court. Only the recoverable costs
established in compliance with these principles is measured against the ceilings (...).
There is a large margin of appreciation for the Court when applying the safeguarding
principles before making a cost decision.
28
When to use both?
Filing UPC Revocation Action shortly before a
(presumably) positive final decision in EPO opposition
proceedings just to recover costs may be not such a good
idea…
Be reasonable rather than greedy, and you will be on the
safe side!
Life Science IP Seminar 2017
29
A Final Thought for the Proprietor…
Do you want to leave your adversary the
choice where to attack your patent
centrally?
If your adversary has missed the 9 month
period, do you want to allow him a 2nd
chance for central attack?
If no, consider opting out!
Opting-out is reversible, so if you want to
enforce your patent before the UPC later,
you can still do it.
Life Science IP Seminar 2017
31
Thank you for your attention!
Dr. Thorsten Bausch [email protected]
European Patent Attorney, Patentanwalt | Partner
Life Science IP Seminar 2017